NewAmsterdam Pharma Company N.V. Announces Positive CHMP Opinion For Obicetrapib And Obicetrapib/Ezetimibe - NAMS News | RalliesNewAmsterdam Pharma Company N.V. Announces Positive CHMP Opinion For Obicetrapib And Obicetrapib/Ezetimibe
N
NAMS• Reuters brief
- NewAmsterdam Pharma Company N.V. announces positive CHMP opinion for obicetrapib and obicetrapib/ezetimibe
- Prevail interim analysis planned for Q4 2026, result expected Q1 2027
- Topline data from Rubens phase 3 expected by year-end 2026
AJG
•
